IMCR
Immunocore Holdings plc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.
Market Cap: 3.08 Billion
Primary Exchange: NASDAQ
Website: immunocore.com
Shares Outstanding: 48.1 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.6472701982239023
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 550 trading days
From: 2021-02-08 To: 2022-09-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|